Quercetin: Dietary sources, functions and health benefits

Quercetin: Dietary Sources, Functions and Health Benefits

Volumn , Issue , 2012, Pages 179-198

  Zhang, Qing Yu ^a   Kong, Ling Dong ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Dietary source; Function; Health benefit; Quercetin

Indexed keywords

EID: 84895310831     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (120)

1. Lamson, D. W. and Brignall, M. S. (2000). Antioxidants and cancer, part 3: quercetin. Alternative Medecine Review, 5, 196-208.
2. Hollman, P. C. H. and Arts, I. C. W. (2000). Flavonols, flavones and flavanols-nature, occurrence and dietary burden. Journal of the Science of Food and Agriculture, 80, 1081-1093.
3. Mendoza-Wilson, A. M. and Glossman-Mitnik, D. (2004). CHIH-DFT determination of the molecular structure, infrared and ultraviolet spectra of the flavonoid quercetin. Journal of Molecular Structure-Theochem, 681, 71-76.
4. Brown, J. P. (1980). A Review of the Genetic-Effects of Naturally-Occurring Flavonoids, Anthraquinones and Related-Compounds. Mutation Research, 75, 243-277.
5. Day, A. J. and Williamson, G. (2000). Human metabolism of dietary quercetin glycoside. Plant Polyphenols 2: Chemistry, Biology, Pharmacology, Ecology, 66, 415-434.
6. Hertog, M. G. L.; Hollman, P. C. H. and Vandeputte, B. (1993). Content of Potentially Anticarcinogenic Flavonoids of Tea Infusions, Wines, and Fruit Juices. Journal of Agricultural and Food Chemistry, 41, 1242-1246.
7. Sampson, L.; Rimm, E.; Hollman, P. C. H.; de Vries, J. H. M. and Katan, M. B. (2002). Flavonol and flavone intakes in US health professionals. Journal of the American Dietetic Association, 102, 1414-1420.
8. Bischoff, S. C. (2008). Quercetin: potentials in the prevention and therapy of disease. Curr. Opinion in Clinical Nutrition and Metabolic Care, 11, 733-740.
9. Kuhnau, J. (1976). The flavonoids. A class of semi-essential food components: their role in human nutrition. World Review of Nutrition and Dietetics, 24, 117-191.
10. Manach, C.; Scalbert, A.; Morand, C.; Remesy, C. and Jimenez, L. (2004). Polyphenols: food sources and bioavailability. The American Journal of Clinical Nutrition, 79, 727-747.
11. Hollman, P. C.; de Vries, J. H.; van Leeuwen, S. D.; Mengelers, M. J. and Katan, M. B. (1995). Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. The American Journal of Clinical Nutrition, 62, 1276-1282.
12. Hollman, P. C. and Katan, M. B. (1997). Absorption, metabolism and health effects of dietary flavonoids in man. Biomed Pharmacother, 51, 305-310.
13. Erlund, I.; Kosonen, T.; Alfthan, G.; Maenpaa, J.; Perttunen, K.; Kenraali, J.; Parantainen, J. and Aro, A. (2000). Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. European Journal of Clinical Pharmacology, 56, 545-553.
14. Kuhnle, G.; Spencer, J. P.; Schroeter, H.; Shenoy, B.; Debnam, E. S.; Srai, S. K.; Rice-Evans, C. and Hahn, U. (2000). Epicatechin and catechin are O-methylated and glucuronidated in the small intestine. Biochemical and Biophysical Research Communications, 277, 507-512.
15. Hollman, P. C.; de Vries, J. H.; van Leeuwen, S. D.; Mengelers, M. J. and Katan, M. B. (1995). Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. The American Journal of Clinical Nutrition, 62, 1276-1282.
16. Conquer, J. A.; Maiani, G.; Azzini, E.; Raguzzini, A. and Holub, B. J. (1998). Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. Journal of Nutrition, 128, 593-597.
17. Hollman, P. C.; vd Gaag, M.; Mengelers, M. J.; van Trijp, J. M.; de Vries, J. H. and Katan, M. B. (1996). Absorption and disposition kinetics of the dietary antioxidant quercetin in man. Free Radical Biology and Medicine, 21, 703-707.
18. Day, A. J.; DuPont, M. S.; Ridley, S.; Rhodes, M.; Rhodes, M. J.; Morgan, M. R. and Williamson, G. (1998). Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver beta-glucosidase activity. FEBS Letters, 436, 71-75.
19. Hackett, A. M. (1986). The metabolism of flavonoid compounds in mammals. Progress in clinical and biological research, 213, 177-194.
20. de Groot, H. (1994). Reactive oxygen species in tissue injury. Hepatogastroenterology, 41, 328-332.
21. Scalbert, A.; Manach, C.; Morand, C.; Remesy, C. and Jimenez, L. (2005). Dietary polyphenols and the prevention of diseases. Critical Reviews in Food Science and Nutrition, 45, 287-306.
22. Diplock, A. T.; Charleux, J. L.; Crozier-Willi, G.; Kok, F. J.; Rice-Evans, C.; Roberfroid, M.; Stahl, W. and Vina-Ribes, J. (1998). Functional food science and defence against reactive oxidative species. British Journal of Nutrition, 80, S77-S112.
23. Lakhanpa, P. and Rai, D. K. (2007). Quercetin: A Versatile Flavonoid. Internet Journal of Medical Update, 2, 22-37.
24. Santos, A. C.; Uyemura, S. A.; Lopes, J. L. C.; Bazon, J. N.; Mingatto, F. E. and Curti, C. (1998). Effect of naturally occurring flavonoids on lipid peroxidation and membrane permeability transition in mitochondria. Free Radical Biology and Medicine, 24, 1455-1461.
25. Croft, K. D.; Loke, W. M.; Proudfoot, J. M.; Mckinley, A. J.; Needs, P. W.; Kroon, P. A. and Hodgson, J. M. (2008). Quercetin and its in vivo metabolites inhibit neutrophil-mediated low-density lipoprotein oxidation. Journal of Agricultural and Food Chemistry, 56, 3609-3615.
26. Shutenko, Z.; Henry, Y.; Pinard, E.; Seylaz, J.; Potier, P.; Berthet, F.; Girard, P. and Sercombe, R. (1999). Influence of the antioxidant quercetin in vivo on the level of nitric oxide determined by electron paramagnetic resonance in rat brain during global ischemia and reperfusion. Biochemical Pharmacology, 57, 199-208.
27. Huk, I.; Brovkovych, V.; Vili, J. N.; Weigel, G.; Neumayer, C.; Partyka, L.; Patton, S. and Malinski, T. (1998). Bioflavonoid quercetin scavenges superoxide and increases nitric oxide concentration in ischaemia-reperfusion injury: an experimental study. British Journal of Surgery, 85, 1080-1085.
28. Chang, W. S.; Lee, Y. J.; Lu, F. J. and Chiang, H. C. (1993). Inhibitory Effects of Flavonoids on Xanthine-Oxidase. Anticancer Research, 13, 2165-2170.
29. Zhu, J. X.; Wang, Y.; Kong, L. D.; Yang, C. and Zhang, X. (2004). Effects of Biota orientalis extract and its flavonoid constituents, quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver. Journal of Ethnopharmacology, 93, 133-140.
30. Arts, M. J. T. J.; Dallinga, J. S.; Voss, H. P.; Haenen, G. R. M. M. and Bast, A. (2004). A new approach to assess the total antioxidant capacity using the TEAC assay. Food Chemistry, 88, 567-570.
31. Heijnen, C. G.; Haenen, G. R.; Oostveen, R. M.; Stalpers, E. M. and Bast, A. (2002). Protection of flavonoids against lipid peroxidation: the structure activity relationship revisited. Free Radical Research, 36, 575-581.
32. Taylor, P. C.; Williams, R. O. and Feldmann, M. (2004). Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases. Current opinion in biotechnology, 15, 557-563.
33. Manjeet K, R. and Ghosh, B. (1999). Quercetin inhibits LPS-induced nitric oxide and tumor necrosis factor-alpha production in murine macrophages. International Journal of Immunopharmacology, 21, 435-443.
34. Boots, A. W.; Haenen, G. R. M. M. and Bast, A. (2008). Health effects of quercetin: from antioxidant to nutraceutical. European Journal of Pharmacology, 585, 325-337.
35. Boots, A. W.; Haenen, G. R. and Bast, A. (2008). Health effects of quercetin: from antioxidant to nutraceutical. European Journal of Pharmacology, 585, 325-337.
36. Nair, M. P.; Mahajan, S.; Reynolds, J. L.; Aalinkeel, R.; Nair, H.; Schwartz, S. A. and Kandaswami, C. (2006). The flavonoid quercetin inhibits proinflammatory cytokine (tumor necrosis factor alpha) gene expression in normal peripheral blood mononuclear cells via modulation of the NF-kappa beta system. Clinical and Vaccine Immunology, 13, 319-328.
37. Overman, A.; Chuang, C. C. and McIntosh, M. (2011). Quercetin attenuates inflammation in human macrophages and adipocytes exposed to macrophage-conditioned media. International Journal of Obesity (Lond)
38. Thornhill, S. M. and Kelly, A. M. (2000). Natural treatment of perennial allergic rhinitis. Alternative medicine review: a journal of clinical therapeutic, 5, 448-454.
39. Borissova, P.; Valcheva, S. and Belcheva, A. (1994). Antiinflammatory effect of flavonoids in the natural juice from Aronia melanocarpa, rutin and rutin-magnesium complex on an experimental model of inflammation induced by histamine and serotonin. Acta Physiologica et Pharmacologica Bulgarica, 20, 25-30.
40. Manson, M. M.; Farmer, P. B.; Gescher, A. and Steward, W. P. (2005). Innovative agents in cancer prevention. Recent Results in Cancer Research, 166, 257-275.
41. Neto, C. C. (2007). Cranberry and its phytochemicals: a review of in vitro anticancer studies. The Journal of Nutrition, 137, 186S-193S.
42. JAN, A. T.; KAMLI, M. R.; MURTAZA, I.; SINGH, J. B.; ALI, A. and HAQ, Q. M. R. (2010). Dietary Flavonoid Quercetin and Associated Health Benefits-An Overview. Food Reviews International, 26, 302-317.
43. Duraj, J.; Zazrivcova, K.; Bodo, J.; Sulikova, M. and Sedlak, J. (2005). Flavonoid quercetin, but not apigenin or luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants. Neoplasma, 52, 273-279.
44. Granado-Serrano, A. B.; Martin, M. A.; Bravo, L.; Goya, L. and Ramos, S. (2006). Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). The Journal of Nutrition, 136, 2715-2721.
45. Mu, C.; Jia, P.; Yan, Z.; Liu, X.; Li, X. and Liu, H. (2007). Quercetin induces cell cycle G(1) arrest through elevating Cdk inhibitors p21 and p27 in human hepatoma cell line (HepG2). Methods and Findings in Experimental and Clinical Pharmacology, 29, 179-183.
46. Lamson, D. W. and Brignall, M. S. (2000). Antioxidants and cancer, part 3: quercetin. Alternative medicine review: a journal of clinical therapeutic, 5, 196-208.
47. Avila, M. A.; Velasco, J. A.; Cansado, J. and Notario, V. (1994). Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468. Cancer Research, 54, 2424-2428.
48. Yoshida, M.; Yamamoto, M. and Nikaido, T. (1992). Quercetin arrests human leukemic T-cells in late G1 phase of the cell cycle. Cancer Research, 52, 6676-6681.
49. Boutin, J. A. (1994). Tyrosine Protein-Kinase Inhibition and Cancer. International Journal of Biochemistry, 26, 1203-1226.
50. Ferry, D. R.; Smith, A.; Malkhandi, J.; Fyfe, D. W.; deTakats, P. G.; Anderson, D.; Baker, J. and Kerr, D. J. (1996). Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clinical Cancer Research, 2, 659-668.
51. Benassayag, C.; Perrot-Applanat, M. and Ferre, F. (2002). Phytoestrogens as modulators of steroid action in target cells. Journal of chromatography B, Analytical technologies in the biomedical and life sciences, 777, 233-248.
52. McDonnell, D. P. and Hall, J. M. (1999). The estrogen receptor beta-isoform (ER beta) of the human estrogen receptor modulates ER alpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology, 140, 5566-5578.
53. van der Woude, H.; Gliszczynska-Swiglo, A.; Struijs, K.; Smeets, A.; Alink, G. M. and Rietjens, I. M. C. M. (2003). Biphasic modulation of cell proliferation by quercetin at concentrations physiologically relevant in humans. Cancer Letters, 200, 41-47.
54. Scambia, G.; Ranelletti, F. O.; Panici, P. B.; Piantelli, M.; Devincenzo, R.; Ferrandina, G.; Bonanno, G.; Capelli, A. and Mancuso, S. (1993). Quercetin Induces Type-Ii Estrogen-Binding Sites in Estrogen-Receptor-Negative (Mda-Mb231) and Estrogen-Receptor-Positive (Mcf-7) Human Breast-Cancer Cell-Lines. International Journal of Cancer, 54, 462-466.
55. Chen, C.; Zhou, J. and Ji, C. (2010). Quercetin: a potential drug to reverse multidrug resistance. Life Sciences, 87, 333-338.
56. Limtrakul, P.; Khantamat, O. and Pintha, K. (2005). Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. Journal of Chemotheraphy, 17, 86-95.
57. Rigano, D.; Formisano, C.; Basile, A.; Lavitola, A.; Senatore, F.; Rosselli, S. and Bruno, M. (2007). Antibacterial activity of flavonoids and phenylpropanoids from Marrubium globosum ssp. libanoticum. Phytotherapy Research, 21, 395-397.
58. Castrillo, J. L. and Carrasco, L. (1987). Action of 3-methylquercetin on poliovirus RNA replication. Journal of virology, 61, 3319-3321.
59. Neznanov, N.; Kondratova, A.; Chumakov, K. M.; Neznanova, L.; Kondratov, R.; Banerjee, A. K. and Gudkov, A. V. (2008). Quercetinase pirin makes poliovirus replication resistant to flavonoid quercetin. DNA and Cell Biology, 27, 191-198.
60. Datla, S. R. and Griendling, K. K. (2010). Reactive Oxygen Species, NADPH Oxidases, and Hypertension. Hypertension (Baltimore), 56, 325-330.
61. Harrison, D. and Kojda, G. (1999). Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovascular Research, 43, 562-571.
62. Mackraj, I.; Govender, T. and Ramesar, S. (2008). The antihypertensive effects of quercetin in a salt-sensitive model of hypertension. Journal of Cardiovascular Pharmacology, 51, 239-245.
63. Sanchez, M.; Galisteo, M.; Vera, R.; Villar, I. C.; Zarzuelo, A.; Tamargo, J.; Perez-Vizcaino, F. and Duarte, J. (2006). Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. Journal of hypertension, 24, 75-84.
64. Aoi, W.; Niisato, N.; Miyazaki, H. and Marunaka, Y. (2004). Flavonoid-induced reduction of ENaC expression in the kidney of Dahl salt-sensitive hypertensive rat. Biochemical Biophysical Research Communications, 315, 892-896.
65. Halperin, R. O.; Sesso, H. D.; Ma, J.; Buring, J. E.; Stampfer, M. J. and Gaziano, J. M. (2006). Dyslipidemia and the risk of incident hypertension in men. Hypertension (Baltimore), 47, 45-50.
66. Prabu, S. M.; Shagirtha, K. and Renugadevi, J. (2010). Amelioration of Cadmium-Induced Oxidative Stress, Impairment in Lipids and Plasma Lipoproteins by the Combined Treatment with Quercetin and alpha-Tocopherol in Rats. Journal of Food Science, 75, T132-T140.
67. Kobori, M.; Masumoto, S.; Akimoto, Y. and Takahashi, Y. (2009). Dietary quercetin alleviates diabetic symptoms and reduces streptozotocin-induced disturbance of hepatic gene expression in mice. Molecular Nutrition and Food Research, 53, 859-868.
68. Rivera, L.; Moron, R.; Sanchez, M.; Zarzuelo, A. and Galisteo, M. (2008). Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring, Md ), 16, 2081-2087.
69. Halaas, J. L.; Gajiwala, K. S.; Maffei, M.; Cohen, S. L.; Chait, B. T.; Rabinowitz, D.; Lallone, R. L.; Burley, S. K. and Friedman, J. M. (1995). Weight-reducing effects of the plasma protein encoded by the obese gene. Science (New York, N Y ), 269, 543-546.
70. Huan, J.-N.; Li, J.; Han, Y.; Chen, K.; Wu, N. and Zhao, A. Z. (2003). Adipocyte-selective reduction of the leptin receptors induced by antisense RNA leads to increased adiposity, dyslipidemia, and insulin resistance. Journal of Biological Chemistry, 278, 45638-45650.
71. Li, J.-M.; Wang, C.; Hu, Q.-H. and Kong, L.-D. (2008). Fructose Induced Leptin Dysfunction and Improvement by Quercetin and Rutin in Rats. Chinese Journal of Natural Medicines, 6, 466-472.
72. Salvi, A.; Carrupt, P.; Tillement, J. and Testa, B. (2001). Structural damage to proteins caused by free radicals: asessment, protection by antioxidants, and influence of protein binding. Biochemical Pharmacology, 61, 1237-1242.
73. Thomson, S. C.; Deng, A.; Bao, D. J.; Satriano, J.; Blantz, R. C. and Vallon, V. (2001). Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. Journal of Clinical Investigation, 107, 217-224.
74. Singh, D.; Chander, V. and Chopra, K. (2004). Quercetin, a bioflavonoid, attenuates ferric nitrilotriacetate-induced oxidative renal injury in rats. Drug and Chemical Toxicology, 27, 145-156.
75. Shoskes, D. A. (1998). Effect of bioflavonoids quercetin and curcumin on ischemic renal injury: a new class of renoprotective agents. Transplantation, 66, 147-152.
76. Prabu, S. M. and Renugadevi, J. (2010). Quercetin protects against oxidative stress-related renal dysfunction by cadmium in rats. Experimental and Toxicologic Pathology, 62, 471-481.
77. Kong, L. D.; Hu, Q. H.; Wang, C. A.; Li, J. M. and Zhang, D. M. (2009). Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: renal organic ion transporter involvement. American Journal of Physiology-Renal Physiology, 297, F1080-F1091.
78. Moore, P. K.; Griffiths, R. J. and Lofts, F. J. (1983). The effect of some flavone drugs on the conversion of prostacyclin to 6-oxoprostaglandin E1. Biochemical Pharmacology, 32, 2813-2817.
79. Neto, C. C. (2007). Cranberry and its phytochemicals: a review of in vitro anticancer studies. The Journal of Nutrition, 137, 186S-193S.
80. Hirvonen, T.; Virtamo, J.; Korhonen, P.; Albanes, D. and Pietinen, P. (2001). Flavonol and flavone intake and the risk of cancer in male smokers (Finland). Cancer Causes and Control: CCC, 12, 789-796.
81. Fotsis, T.; Pepper, M. S.; Aktas, E.; Breit, S.; Rasku, S.; Adlercreutz, H.; Wahala, K.; Montesano, R. and Schweigerer, L. (1997). Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Research, 57, 2916-2921.
82. Fan, T. P.; Jaggar, R. and Bicknell, R. (1995). Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends in Pharmacological Sciences, 16, 57-66.
83. Cruz-Correa, M.; Shoskes, D. A.; Sanchez, P.; Zhao, R.; Hylind, L. M.; Wexner, S. D. and Giardiello, F. M. (2006). Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clinical Gastroenterology and Hepatology, 4, 1035-1038.
84. Hanninen; Kaartinen, K.; Rauma, A. L.; Nenonen, M.; Torronen, R.; Hakkinen, A. S.; Adlercreutz, H. and Laakso, J. (2000). Antioxidants in vegan diet and rheumatic disorders. Toxicology, 155, 45-53.
85. Boots, A. W.; Drent, M.; de Boer, V. C. J.; Bast, A. and Haenen, G. R. M. M. (2011). Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clinical Nutrition (Edinburgh, Scotland), 30, 506-512.
86. Walgren, R. A.; Karnaky, K. J., Jr.; Lindenmayer, G. E. and Walle, T. (2000). Efflux of dietary flavonoid quercetin 4'-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. The Journal of Pharmacology and Experimental Therapeutics, 294, 830-836.
87. Manach, C.; Mazur, A. and Scalbert, A. (2005). Polyphenols and prevention of cardiovascular diseases. Current Opinion in Lipidology, 16, 77-84.
88. Knekt, P.; Jarvinen, R.; Reunanen, A. and Maatela, J. (1996). Flavonoid intake and coronary mortality in Finland: a cohort study. British Medical Journal (Clinical research ed ), 312, 478-481.
89. Terao, J.; Kawai, Y. and Murcita, K. (2008). Vegetable flavonoids and cardiovascular disease. Asia Pacific Journal of Clinical Nutrition, 17, 291-293.
90. Gryglewski, R. J.; Korbut, R.; Robak, J. and Swies, J. (1987). On the mechanism of antithrombotic action of flavonoids. Biochemical Pharmacology, 36, 317-322.
91. Edwards, R. L.; Lyon, T.; Litwin, S. E.; Rabovsky, A.; Symons, J. D. and Jalili, T. (2007). Quercetin reduces blood pressure in hypertensive subjects. The Journal of nutrition, 137, 2405-2411.
92. Oiry, C.; Youl, E.; Bardy, G.; Magous, R.; Cros, G.; Sejalon, F.; Virsolvy, A.; Richard, S.; Quignard, J. F.; Gross, R.; Petit, P. and Bataille, D. (2010). Quercetin potentiates insulin secretion and protects INS-1 pancreatic beta-cells against oxidative damage via the ERK1/2 pathway. British Journal of Pharmacology, 161, 799-814.
93. Suchankova, G.; Nelson, L. E.; Gerhart-Hines, Z.; Kelly, M.; Gauthier, M. S.; Saha, A. K.; Ido, Y.; Puigserver, P. and Ruderman, N. B. (2009). Concurrent regulation of AMP-activated protein kinase and SIRT1 in mammalian cells. Biochemical and Biophysical Research Communications, 378, 836-841.
94. Du, L. and Xie, W. (2011). Diabetes is an inflammatory disease: evidence from traditional Chinese medicines. Diabetes Obesity and Metabolism, 13, 289-301.
95. Liu, J.; Yu, H. and Ning, X. (2006). Effect of quercetin on chronic enhancement of spatial learning and memory of mice. Science China Series C: Life Sciences, 49, 583-590.
96. Navon, A. and Ciechanover, A. (2009). The 26 S proteasome: from basic mechanisms to drug targeting. The Journal of Biological Chemistry, 284, 33713-33718.
97. Chondrogianni, N.; Kapeta, S.; Chinou, I.; Vassilatou, K.; Papassideri, I. and Gonos, E. S. (2010). Anti-ageing and rejuvenating effects of quercetin. Experimental gerontology, 45, 763-771.
98. Gonos, E. S. and Chondrogianni, N. (2005). Proteasome dysfunction in mammalian aging: Steps and factors involved. Experimental gerontology, 40, 931-938.
99. Saag, K. G. and Choi, H. (2006). Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Research and Therapy, 8 Suppl 1, S2.
100. Nuki, G. and Simkin, P. A. (2006). A concise history of gout and hyperuricemia and their treatment. Arthritis Research and Therapy, 8
101. Kong, L. D.; Mo, S. F.; Zhou, F.; Lv, Y. Z.; Hu, Q. H. and Zang, D. M. (2007). Hypouricemic action of selected flavonoids in mice: Structure-activity relationships. Biological and Pharmaceutical Bulletin, 30, 1551-1556.
102. Hu, Q.-H.; Wang, C.; Li, J.-M.; Zhang, D.-M. and Kong, L.-D. (2009). Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: renal organic ion transporter involvement. American Journal of Physiology-Renal Physiology, 297, F1080-F1091.
103. Floyd, R. A. (1999). Antioxidants, oxidative stress, and degenerative neurological disorders. Experimental Biology and Medicine, 222, 236-245.
104. Heo, H. J. and Lee, C. Y. (2004). Protective effects of quercetin and vitamin C against oxidative stress-induced neurodegeneration. Journal of Agricultural and Food Chemistry, 52, 7514-7517.
105. Prouillet, C.; Maziere, J.-C.; Maziere, C.; Wattel, A.; Brazier, M. and Kamel, S. (2004). Stimulatory effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblasts through ERK and estrogen receptor pathway. Biochemical Pharmacology, 67, 1307-1313.
106. Hegarty, V. M.; May, H. M. and Khaw, K. T. (2000). Tea drinking and bone mineral density in older women. The American Journal of Clinical Nutrition, 71, 1003-1007.
107. Gugler, R.; Leschik, M. and Dengler, H. J. (1975). Disposition of Quercetin in Man after Single Oral and Intravenous Doses. European Journal of Clinical Pharmacology, 9, 229-234.
108. Jorgensen, L. V.; Cornett, C.; Justesen, U.; Skibsted, L. H. and Dragsted, L. O. (1998). Two-electron electrochemical oxidation of quercetin and kaempferol changes only the flavonoid C-ring. Free Radical Research, 29, 339-350.
109. Awad, H. M.; Boersma, M. G.; Boeren, S.; van Bladeren, P. J.; Vervoort, J. and Rietjens, I. M. (2002). The regioselectivity of glutathione adduct formation with flavonoid quinone/quinone methides is pH-dependent. Chemical Research in Toxicology, 15, 343-351.
110. Vrijsen, R.; Michotte, Y. and Boeye, A. (1990). Metabolic activation of quercetin mutagenicity. Mutation Research, 232, 243-248.
111. Jurado, J.; Alejandre-Duran, E.; Alonso-Moraga, A. and Pueyo, C. (1991). Study on the mutagenic activity of 13 bioflavonoids with the Salmonella Ara test. Mutagenesis, 6, 289-295.
112. Cross, H. J.; Tilby, M.; Chipman, J. K.; Ferry, D. R. and Gescher, A. (1996). Effect of quercetin on the genotoxic potential of cisplatin. International Journal of Cancer, 66, 404-408.
113. Czeczot, H. (1994). Mutagenic activity of quercetin in derivatives of Escherichia coli WP2 uvrA with increased permeability. Acta Biochimica Polonica, 41, 144-147.
114. Czeczot, H. and Kusztelak, J. (1993). A study of the genotoxic potential of flavonoids using short-term bacterial assays. Acta biochimica Polonica, 40, 549-554.
115. Caria, H.; Chaveca, T.; Laires, A. and Rueff, J. (1995). Genotoxicity of quercetin in the micronucleus assay in mouse bone marrow erythrocytes, human lymphocytes, V79 cell line and identification of kinetochore-containing (CREST staining) micronuclei in human lymphocytes. Mutation Research, 343, 85-94.
116. Silva, I. D.; Gaspar, J.; da Costa, G. G.; Rodrigues, A. S.; Laires, A. and Rueff, J. (2000). Chemical features of flavonols affecting their genotoxicity. Potential implications in their use as therapeutical agents. Chemico-Biological Interactions, 124, 29-51.
117. Vanderhoeven, J. C. M.; Bruggeman, I. M. and Debets, F. M. H. (1984). Genotoxicity of Quercetin in Cultured Mammalian-Cells. Mutation Research, 136, 9-21.
118. Choi, K. E.; Choi, J. S. and Choi, B. C. (2004). Effect of quercetin on the pharmacokinetics of oral cyclosporine. American Journal of Health-System Pharmacy, 61, 2406-2409.
119. Joseph, L. W. (1993). Nutritional Influences on Mental-Illness-a Sourcebook of Clinical Research-Werbach, Mr. Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie, 38, 235-235.
120. Walle, T.; Otake, Y.; Walle, U. K. and Wilson, F. A. (2000). Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption. The Journal of nutrition, 130, 2658-2661.